PatentsDB

Method for providing diagnosis of cancer using seprase as a marker

US8980573B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-8980573-B2
Application numberUS-79194610-A
CountryUS
Kind codeB2
Filing dateJun 2, 2010
Priority dateDec 10, 2007
Publication dateMar 17, 2015
Grant dateMar 17, 2015

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP/seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific types of cancer. Such specific cancer types are, e.g., esophagus, head and neck cancer, stomach cancer, bile duct cancer, pancreas cancer, kidney cancer, cervix cancer, ovary cancer, breast cancer, bladder cancer, endometrium cancer or prostate cancer. Furthermore, it especially relates to a method for assessing cancer from a liquid sample, derived from an individual by measuring seprase in said sample. Measurement of seprase can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.

First claim

Opening claim text (preview).

What is claimed is: 1. A method for providing a diagnosis of cancer in a subject suspected of having at least one of lung cancer, colon cancer, esophageal cancer, head and neck cancer, stomach cancer, bile duct cancer, pancreatic cancer, kidney cancer, cervical cancer, ovarian cancer, breast cancer, bladder cancer, endometrial cancer and prostate cancer, comprising: contacting, in vitro, a portion of a sample selected from the group consisting of serum and plasma from a subject wi…

Assignees

Inventors

Classifications

Patent family

Related publications grouped by family.

View patent family 40373548

External sources

Next steps

Free tools are coming soon. Tell us what you want to track and we'll notify you.

Get alerts for this patentView on Google Patents

Request deeper analysis

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US8980573B2 cover?
The present invention relates to a method aiding in the assessment of cancer. It discloses the use of the human fibroblast activation protein (FAP/seprase) as a universal marker of different cancer types. Seprase aids in the assessment of pulmonary or lung cancer (LC) or of colon cancer, e.g., of non-small cell lung carcinoma (NSCLC) or colorectal cancer (CRC), but also likely of other specific…
Who is the assignee on this patent?
Rollinger Wolfgang, Karl Johann, Kochan Jarema Peter, and 3 more
What technology area does this patent fall under?
Primary CPC classification G01N33/5752. Mapped technology areas include Physics.
When was this patent published?
Publication date Tue Mar 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).